Le Lézard
Classified in: Health
Subjects: NPT, WOM, TRI

International Experts Provide Consensus on How to Administer Testosterone to Postmenopausal Women


BURNSVILLE, Minn., April 1, 2021 /PRNewswire/ -- Today, the International Society for the Study of Women's Sexual Health (ISSWSH) published an in-depth, detailed evidence-based, peer-reviewed international guideline on how healthcare professionals should administer testosterone to postmenopausal women. Although women naturally produce significant quantities of testosterone from puberty on, by the time they reach menopause, about 50% of their body's testosterone has been lost. Such deficiency leads to reduced muscle mass and strength, increased body fat, and not infrequently to the sexual dysfunction commonly referred to as lost libido. For years, men have had many FDA-approved testosterone therapies, including less expensive generics. Women still have no FDA approved options. Against this void of FDA-approved options for women, healthcare professionals have devised many schemes to address their patients' testosterone needs. These include using custom compounded therapies warned against by the FDA and men's products "off-label" in women which may not be prescribed correctly. Unfortunately, these approaches can result in significant androgen excess side-effects like acne, facial hair, voice changes, and balding. Some of these unfortunate outcomes are irreversible. Today's publication is so important that it appears simultaneously in three academic journals: The Journal of Sexual Medicine, the official journal of the International Society of Sexual Medicine (ISSM) and The International Society for the Study of Women's Sexual Health (ISSWSH); Climacteric, The official Journal of the International Menopause Society (IMS), and The Journal of Women's Health, the official journal of the Academy of Women's Health and the American Medical Women's Association.

Testosterone therapy for HSDD in women: Recommended patient ID, lab testing, dosing, monitoring, and follow-up care

Article: Clinical Practice Guideline for the Use of Systemic Testosterone for Hypoactive Sexual Desire Disorder in Women

About ISSWSH: The International Society for the Study of Women's Sexual Health (ISSWSH) is a multi-disciplinary society dedicated to providing opportunities for communication among scholars, researchers, and practitioners about women's sexual health; supporting the highest standards of ethics and professionalism in research, education, and clinical practice of women's sexual health, and providing the public with accurate information about women's sexual health. ISSWSH has taken on the challenge of teaching clinicians about women's sexual health, following the mandate of the World Health Organization (WHO) that all women deserve good health, including sexual health.

www.isswsh.org
Facebook [https://www.facebook.com/isswshoffice/] @isswshoffice
Twitter [https://twitter.com/ISSWSH] @isswsh
Instagram [https://www.instagram.com/isswshoffice/] @isswshoffice

SOURCE International Society for the Study of Women's Sexual Health (ISSWSH)


These press releases may also interest you

at 17:49
The ALS Association today celebrated the beginning of ALS Awareness Month and the 10th Anniversary of the Ice Bucket Challenge, which inspired the world to join the fight against ALS in the summer of 2014. Throughout May and the summer, the ALS...

at 17:31
White Glove Placement, a leading provider of staffing solutions for healthcare facilities, is proud to announce its "Scoops of Gratitude" Free Ice Cream Truck to celebrate Nurses Week and show appreciation for the dedication and hard work of nurses...

at 17:31
DelveInsight's Opioid Withdrawal...

at 17:30
Two El Camino Health hospitals in the South Bay have earned the highest ranking for patient safety from The Leapfrog Group, a national, not-for-profit, independent evaluator that measures excellence in patient care. This national distinction marks...

at 17:25
Myomo, Inc. ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced that it will report financial results for the...

at 17:23
EVP Capital Inc. ("EVP Capital"), a capital pool company ("CPC") listed on the TSX Venture Exchange Inc. (the "Exchange"), is pleased to announce that it has entered into a non-binding letter of intent dated May 1, 2024 (the "LOI") with Sharp Edge...



News published on and distributed by: